The ad-ABM: quantifying the impacts of reducing exposure to environmental toxins on onset and progression of alzheimer's disease and related dementias using agent-based modeling
Active Grant Awarded
- Award ID
- R21AG101382
- Recipient
-
Icahn School Of Medicine At Mount Sinai UEI C8H9CNG1VBD9
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $476,918
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 10% complete
- Place of performance
- New York, NY 10029, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services' National Institutes of Health, through the National Institute on Aging, awarded Icahn School of Medicine at Mount Sinai a grant totaling $476,918 on September 9, 2026, under Assistance Listing 93.866, Aging Research. The award funds an agent-based modeling project that quantifies how reducing exposure to environmental toxins affects the onset and progression of Alzheimer's disease and related dementias (AD/ADRD). The project extends a preliminary AD-ABM docked to participant characteristics of the National Alzheimer's Coordinating Centers Uniform Data Set (NACC; N>50,000). The model is designed to simulate peer influence on uptake of exposure-reducing behaviors across social networks and to test what-if scenarios on population-level AD/ADRD outcomes. Dollars obligated total $476,918, and the period of performance runs from the September 9, 2026 award date to an ultimate completion date of August 31, 2028. Work is performed in New York, NY 10029. The Aging Research program supports biomedical, social, and behavioral research and training on the aging process, with a particular emphasis on preventing and treating Alzheimer's disease and its related dementias.
Description
- Abstract
- Reducing exposure to environmental toxins may be an understudied, modifiable way to decrease the population-level burden of alzheimer's disease and related dementias (ad/ADRD). However, our ability to study how reducing environmental toxin exposures over the lifespan could impact ad/ADRD prevalence and incidence in large populations is limited by two major gaps in the field: 1) studies have either well- characterized environmental toxin data or well-characterized neuro-phenotyping data - but rarely both, and rarely over the entire life course. 2) we lack a framework to study the impacts of reducing environmental toxin exposures in real-world settings that accounts for the rich heterogeneity of people, their behaviors, and their interactions with the environment, over time. Agent-based modeling (ABM) can fill this GAP. ABM is a data science microsimulation approach for studying how changes in modifiable factors, and interactions between those modifiable factors, can impact complex systems over time. ABM enables use of multiple data sources and effect sizes from the literature to simultaneously inform the model, to emulate disease progression dynamics in real world data. IT can also model the impact of peer influences on behavioral changes (e.g. uptake of behaviors to reduce environmental toxin exposure) across social networks. Abms can be used as virtual laboratories to test what-if scenarios on population-level ad/ADRD outcomes. Our team has built a preliminary ad-ABM by leveraging prospective neuro-phenotyping data from across the united states using the national alzheimer's coordinating centers uniform data set (nacc; N>50,000). Our preliminary ad-ABM is docked to key participant characteristics of the nacc dataset, and replicates the 10-year incidence of mild cognitive impairment (MCI) and dementia in nacc data for participants who were cognitively unimpaired at baseline, showing that our ad-ABM can emulate real-world disease progression dynamics. In this R21, we will refine our preliminary ad-ABM, by augmenting IT with rich neurophenotyping data, CO-morbidities, environmental influences and hypothetical social networks. We will then use this virtual laboratory to test the impacts of reducing exposure to different environmental toxins in mid-life, including smoking cessation and toxic metals. We will quantify the impacts on the prevalence and incidence of MCI and dementia over ten years, as well as modeling cognitive decline as a continuous variable. Data sources informing our ABM include nacc, the national health and nutrition examination survey, health and retirement study, the ad knowledge portal and effect sizes from the literature. Lasty, we will pilot a user-friendly dashboard that can enable researchers to use our virtual laboratory for themselves, to trial how different levels of reduction to environmental toxin exposure can impact population-level ad/ADRD outcomes. Our long-term goal is to develop a comprehensive ad-ABM to test the impacts of modifying environmental toxin exposures across the lifespan for ad/ADRD prevention.
Quick answers
Who received award R21AG101382?
R21AG101382 was awarded to Icahn School Of Medicine At Mount Sinai by National Institute on Aging (National Institutes of Health) on September 9, 2026.
How much is award R21AG101382 worth?
$476,918 has been obligated on R21AG101382.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award